invasive melanoma that shares properties of LM, as well as exhibiting the metastatic potential of malignant melanoma. Unfortunately, LM/LMM diagnosis based on dermoscopy is rather ambiguous, and these lesions are often mistaken for junctional dysplastic nevi over sun-damaged skin, pigmented actinic keratosis, solar lentigo, or seborrheic keratosis. Diagnosis must be made on biopsy using distinct dermatopathologic features. These include a pagetoid appearance of melanocytes, melanocyte atypia, 
INTRODUCTION
Lentigo maligna (LM) is a pigmented skin lesion that is often mistaken for a ''benign-type'' lesion. However, to date, no longitudinal studies have proven this assumption. In fact, recent research is pointing to a continuous clinical and pathological spectrum of skin cancer spanning lentigo, LM, and lentigo-maligna melanoma (LMM) in the same fashion as benign nevus, melanoma in situ, and invasive melanoma. LM is currently considered to be ''melanoma in situ'', with a 5-20% lifetime risk of progression to LMM [1] , and represents 4-15% of all invasive melanomas [2] , with properties of LM plus the metastatic potential of malignant melanoma [1, [3] [4] [5] . At this point, it is the dermatologist's and dermatopathologist's challenge to assess the risk of invasive potential of each pigmented lesion and to prevent further morbidity and mortality from melanoma transformation. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
LM and LMM
LM, formerly known as a Hutchinson melanotic freckle, is defined as ''melanoma in situ'' occurring at a site of chronic sun exposure. In 5-20% of patients, it will develop into an invasive melanoma, most often of the aggressive desmoplastic melanoma subtype [1] . This progression can take anywhere from less than 10 years to more than 50 years, and any time in between. Confusing as these statistics may seem, these data come from studies completed 30 years ago and have not yet been refuted [1, [3] [4] [5] . The probability that LM transforms into a melanoma increases if the LM exhibits variation in color, expanding surface area, increasing border irregularity, and/or development of elevated areas [1, [3] [4] [5] .
LMM, on the other hand, is a subset of melanoma that accounts for 4-15% of melanoma diagnoses [1, [3] [4] [5] . Early studies suggested a lifetime risk of developing LMM from LM of 5% [6] ; however, more recent work suggests that this number may be as high as 20% [7] [8] [9] . Ultraviolet radiation-induced mutation of the hair follicle has been suggested as the cause of LMM, producing a fairly aggressive and deep skin cancer [3, 4] .
LMM is so named because it demonstrates features of LM in its in situ component, while also displaying features typical of invasive melanoma [1, [3] [4] [5] . Risk factors that predispose a patient to either LM or LMM include light skin that freckles, a history of non-melanoma skin cancer, and a history of sun damage/burn. However, the development of LM/LMM has no reported dose-effect relationship with respect to an individual's cumulative sun damage or an association with the genetic propensity of an individual to form nevi [10, 11] (Fig. 1 ).
LM and LMM have similar clinical presentation. The lesions are both found in chronically sun-exposed areas, often of the nose, cheeks, and ears (not often on the upper Fig. 1 Pigmented lesion of the cheek in an elderly man. Biopsy showed atypical intraepidermal melanocytic proliferation extending to the lateral margins. With anti-melan-A staining, a final diagnosis of melanoma in situ was made back, forearms, or legs). The peak incidence for both lesions is 65-80 years of age, but in recent years there has been increasing incidence in younger age groups (40-65 years), as witnessed in a cohort from northern California [1, 3, 12] . Characteristically, an LM/LMM will present as an atypical, non-scaly pigmented patch with ill-defined borders and variable size, shape, or shade (from tan to black to the rare amelanotic).
These skin lesions grow radially and may grow/ regress in a pattern that makes the LM/LMM appear to ''move across'' the skin [1, 3] 
Differential Diagnoses of LM/LMM
The differential diagnosis of LM/LMM includes myriad other pigmented skin lesions, including solar lentigo, seborrheic keratosis, lichen planus-like keratosis, junctional dysplastic nevus over sun damage, and pigmented AK [14] [15] [16] .
However, there are distinct differences that can be used to distinguish between these differential diagnoses and the diagnosis of LM/LMM. One of the most under-recognized differential diagnosis for LM/LMM is the pigmented AK [14] . Pigmented AKs are areas of skin that are damaged with ultraviolet radiation and are considered ''pre-cancerous''. Without treatment, they may progress to either a squamous cell carcinoma (SCC) within 2 years or a basal cell carcinoma (BCC) [17, 18] . Based on reporting as of 2012, it is thought that pigmented AKs arise as a collision between a non-pigmented AK and a separate but coexistent pigmented lesion such as a solar lentigo. Therefore, the pigmentation within a pigmented AK is not believed to be due to changes in the quality or quantity of melanocytes, as in a melanoma [19] . Histologically, a pigmented AK will show signs of apoptotic keratinocytes in the epidermis and upper dermis, hyperkeratosis/parakeratosis, melanophages in the papillary dermis, and increased melanin deposition [20, 21] .
Dermoscopy of LM/LMM Versus Pigmented AK
Under the dermatoscope, a pigmented AK will have characteristics such as asymmetric pigmented follicular openings, hyperpigmentation of the follicle rim, light brown pseudo-networks, light rhomboidal structures, light streaks, and peripheral grey dots. Though these features are very similar to those found with LM/LMM dermoscopy, the lighter color pigment differentiates pigmented AK from LM/LMM [13] .
There are three dermoscopic criteria that significantly differentiate a pigmented AK from a malignant LM/LMM: dark rhomboidal structures, dark streaks, and black blotches.
Dark streaks and blotches are specific for LM/ LMM at a rate of 97% and 100%, respectively [13] .
LM skin lesions show characteristic black blotches, asymmetric hyperpigmented rims around follicular openings, dark rhomboidal structures (pigmented lines surrounding appendageal openings), asymmetric peripheral dark grey dots (indicative of superficial melanotic lesions, with a greater asymmetry proportional to greater malignancy), and annular-granular structures [13] . LMM skin lesions demonstrate features such as a target-like pattern (there is no definitive pathological correlate to date, but it is believed to be related to pilar infundibulum invasion), increased vascular density, dark streaks, and either an annular-granular or peppering pattern [22] . Four features in particular are hallmarks of LMM: asymmetric pigmented follicular openings, dark rhomboidal structures, slate-grey areas, and slate-grey dots/globules/ pepper pattern. If all these structures are found in one lesion, they have 89% sensitivity and 96% specificity for a diagnosis of LMM [1, 13, 23, 24] (Table 1) .
Diagnosis of LM/LMM
The gold standard of LM/LMM diagnosis is the skin biopsy [1] ; however, this standard is very limited in light of the high rate of diagnostic discordance among dermatopathologists [27] .
Excisional biopsy is the optimal method, but may not be possible due to the size of the lesion or its location at a critical site such as the eyelid margin. An incisional biopsy site is chosen based on the most clinically significant areas by dermoscopic and clinical examination; unfortunately, due to site selection, there may be a risk of sampling error. In addition, it is also possible to perform a deep saucerization shave biopsy [1] . Both incisional and saucerization shave biopsies risk transection of the LM/LMM, therefore impacting histological diagnosis, although a recent study showed that melanoma transection does not necessarily impact overall disease-free survival or patient mortality [28] . On pathology, the diagnosis of 16, 26] . LM/LMM is notorious for skip areas on biopsy, leading to false-negative margins, and therefore it is often necessary to biopsy a larger area to determine where the true margins of the lesion lie [25] . Sometimes it may be useful to biopsy a ''negative control'' in an area of sun-damaged skin that appears normal; this will provide an individual's background level of melanocytic hyperplasia/atypia that can serve as a reference [26] . Unfortunately, the diagnosis of LM/LMM is difficult, and there is not a high degree of concordance among dermatopathologists in interpreting excision margins [27] .
To assist in the diagnosis of LM/LMM, a variety of immunostaining is available that can specifically mark melanocytes. HMB-45 (human melanoma black) is a monoclonal antibody that reacts against the antigen Pmel 17 in human melanocytic tumors; MART-1 (protein melan-A or melanoma antigen recognized by T cells) is a melanocyte surface antigen that is useful as a biomarker in melanocytic tumors (however, it is less specific, as it is found in benign nevi as well) [31, 32] (Table 2) . [33, 34] . A subsequent study determined that the sensitivity of R21 in detecting LM was 88% [34] . Though R21 immunostaining is very promising, R21 is not widely used due to limited availability [33, 34] (Fig. 2) . To date, there have been no formal clinical trials in which wide local excision has been evaluated with regard to optimal margins for LM/LMM, but a report from 2012 determined that 9-mm margins were adequate for complete clearance of the lesion in 99% of cases [36] . However, the recurrence rate with this technique is 6-9% over 3 to 3.5 years. Histological visualization may not be adequate in all cases, and removal of subclinical peripheral tissue may not be possible due to adjacent follicular involvement or the ''field effect'', in which an extension of atypical melanocytes leads to a recurrence at the periphery of the treated area [10, 36, 37] (Fig. 3) .
Overview of Treating LM/LMM
Mohs microscopic surgery uses frozen Staged excision with rush permanent sections (a.k.a. ''slow Mohs'') is thought to be the optimal treatment for LM/LMM, with recurrence of 0-5% at 23-57 months [10] . The most common surgery is geometric excision Fig. 3 Pigmented lesion of the cheek in a middle-aged woman. a Pigmented lesion before removal; b surgical borders as defined by Wood's lamp; c surgical removal of the lesion; d H&E staining on low-power view (910); e H&E staining on higher-power view (920); f H&E staining on high-power view (940). After removal of the lesion, dermatopathology revealed atypical intraepidermal melanocytic proliferation overlying dermal elastosis extending to all margins; the final diagnosis was melanoma in situ on sun-damaged skin. Even with borders defined by Wood's lamp, the dermatopathologist deemed it necessary to go back and surgically remove more at all the margins. H&E hematoxylin and eosin [40] , although there are several variations of this surgical method, including square, perimeter, contoured, and spaghetti [41] [42] [43] [44] . It is important to note that although LMM is considered a lower-risk melanoma, it still must be treated as a melanoma and excised with borders, consistent with standard treatment.
However, the cons of this type of treatment include the time between each stage of excision and the inability to visualize all margins of the lesion, depending on the type of staged excision [46] , radiotherapy [46] [47] [48] , the use of Grenz rays [49] , laser surgery including Q-switched Nd:YAG and CO 2 (these treatments have the highest 5-year recurrence rate, at 43%) [1, 35, 50, 51] , electrodesiccation with curettage [1, 35] , photodynamic therapy [52] , and 5% topical imiquimod (which may also be useful in treating amelanotic LM/LMM) [47, [53] [54] [55] [56] . Radiotherapy is considered a superior non-invasive treatment method, as it may eradicate potentially invasive components of LM [46] [47] [48] . However, if this is not an option, combining non-surgical techniques with superior imaging (such as confocal microscopy) may also allow for appropriate assessment of response to therapy (Table 3 ).
In the follow-up of LM/LMM treatment, it is important to be aware of the field effect with extension of atypical melanocytes at the periphery of the treated area, which may occur after many years of remission [37] . The National
Cancer Institute suggests follow-up every 3 to 6 months for the first 2 years after treatment and annually thereafter [57] .
CONCLUSIONS
LM is a pigmented lesion that can undergo malignant transformation from low-grade to particularly aggressive forms of melanoma.
Perhaps similar to the spectrum of malignancy from AK to SCC [58] , LM and LMM lie on their own dermatologic spectrum from melanoma in situ to malignant melanoma. 
